Article
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.
Future oncology (London, England) - 1 Nov 2019
Rossi Sabrina, Finocchiaro Giovanna, Noia Vincenzo Di, Bonomi Maria, Cerchiaro Eleonora, Rose Fiorenza De, Franceschini Davide, Navarria Pierina, Ceresoli Giovanni Luca, Beretta Giordano Domenico, D'Argento Ettore, Scorsetti Marta, Santoro Armando, Toschi Luca
Abstract excerpt
Aim: The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy in EGFR-mutated non-small-cell lung cancer patients experiencing disease progression under TKIs could be a valid an option. Patients & methods: We included 131 patients experiencing disease progression during first-line TKI. In group A, patients received TKI beyond progression and site(s) of progression were irradiated; in group B,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.